SMTL ID : 8v81.1

Phosphorylated, ATP-bound, inhibitor 172-bound E1371Q human cystic fibrosis transmembrane conductance regulator

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

monomer

Ligands

2 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 3 residues within 4Å: Chain A: T.463, Q.491 Ligands: ATP.3 1 PLIP interactions: 1 interactions with chain A Metal complexes: A:T.463 MG.2: 3 residues within 4Å: Chain A: S.1249, Q.1289 Ligands: ATP.4 1 PLIP interactions: 1 interactions with chain A Metal complexes: A:S.1249

2 x ATP: ADENOSINE-5'-TRIPHOSPHATE(Non-covalent)

ATP.3: 16 residues within 4Å: Chain A: W.399, V.438, T.458, G.459, G.461, K.462, T.463, S.464, Q.491, Q.1328, C.1342, V.1343, S.1345, H.1346, G.1347 Ligands: MG.1 11 PLIP interactions: 11 interactions with chain A Hydrogen bonds: A:G.459, A:G.461, A:K.462, A:T.463, A:S.464, A:C.1342, A:G.1347 Salt bridges: A:K.462, A:K.462 pi-Stacking: A:W.399, A:W.399 ATP.4: 16 residues within 4Å: Chain A: I.544, T.545, S.547, G.549, Q.550, N.963, Y.1217, T.1244, G.1245, S.1246, G.1247, K.1248, S.1249, T.1250, Q.1289 Ligands: MG.2 14 PLIP interactions: 14 interactions with chain A Hydrogen bonds: A:I.544, A:S.547, A:G.549, A:Q.550, A:N.963, A:G.1245, A:G.1247, A:K.1248, A:S.1249, A:T.1250, A:Q.1289 Salt bridges: A:K.1248 pi-Stacking: A:Y.1217, A:Y.1217

5 x POV: (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate(Non-covalent)(Non-functional Binders)

POV.5: 3 residues within 4Å: Chain A: V.91, L.208 Ligands: CLR.10 2 PLIP interactions: 2 interactions with chain A Hydrophobic interactions: A:V.91, A:L.208 POV.6: 0 residues within 4Å: (No contacts) No protein-ligand interaction detected (PLIP) POV.7: 1 residues within 4Å: Chain A: Y.360 2 PLIP interactions: 2 interactions with chain A Hydrophobic interactions: A:Y.360, A:Y.360 POV.8: 0 residues within 4Å: (No contacts) No protein-ligand interaction detected (PLIP) POV.9: 2 residues within 4Å: Chain A: L.98, R.102 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:L.98

1 x CLR: CHOLESTEROL(Non-covalent)

CLR.10: 4 residues within 4Å: Chain A: L.208, G.211, E.215 Ligands: POV.5 2 PLIP interactions: 2 interactions with chain A Hydrophobic interactions: A:L.208, A:E.215

1 x WG5: 4-[(Z)-{(3M)-4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene}methyl]benzoic acid(Non-covalent)

WG5.11: 13 residues within 4Å: Chain A: K.93, F.308, I.342, M.346, G.919, A.921, D.922, I.998, A.1002, N.1136, I.1137, T.1140, W.1143 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:I.342, A:D.922, A:W.1143 Salt bridges: A:K.93

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Gao, X. et al., Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore. Nat Commun (2024)

Release Date

2024-07-17

Peptides

Cystic fibrosis transmembrane conductance regulator: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Membrane

We predict this structure to be a membrane protein.
Show / Hide

Cystic fibrosis transmembrane conductance regulator